Riyati Mediquip Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 06-07-2024
- Paid Up Capital ₹ 0.10 M
as on 06-07-2024
- Company Age 18 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -78.35%
(FY 2022)
- Profit -8.72%
(FY 2022)
- Ebitda -37.93%
(FY 2022)
- Net Worth 11.34%
(FY 2022)
- Total Assets 3.24%
(FY 2022)
About Riyati Mediquip
The Corporate was formerly known as Damodar Fashion Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Manoj Sharma and Shweta Sharma serve as directors at the Company.
- CIN/LLPIN
U33111DL2006PTC152390
- Company No.
152390
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Aug 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Riyati Mediquip Private Limited offer?
Riyati Mediquip Private Limited offers a wide range of products and services, including Industrial Fabrics and Textiles, Non Woven Fabric, Hand Sanitizers & Personal Hygiene, Hand Sanitizer & Disinfectant, Physiotherapy & Rehab Aids, Vacuum Therapy & Laser Therapy Equipments, ECP Machine, Bathroom Accessories, Soap & Sanitizer Dispenser, Face Mask & Medical PPE Kits.
Who are the key members and board of directors at Riyati Mediquip?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Sharma  | Additional Director | 16-Mar-2012 | Current |
| Shweta Sharma | Additional Director | 05-Mar-2012 | Current |
Financial Performance and Corporate Structure Insights of Riyati Mediquip.
Riyati Mediquip Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 78.35% decrease. The company also saw a slight decrease in profitability, with a 8.72% decrease in profit. The company's net worth Soared by an impressive increase of 11.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Riyati Mediquip?
In 2021, Riyati Mediquip had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Riyati Mediquip?
Unlock and access historical data on people associated with Riyati Mediquip, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Riyati Mediquip, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Riyati Mediquip's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
